Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090 , WKN: 632313

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Three Earnings Reports Put the Automation Rally to the Test

2026-08-27
Three robotics earnings reports from Cognex, Omnicell, and UiPath test whether the automation rally is fundamentals-driven or just momentum.

Omnicell: Offers Good Value, But Uncertainty Remains

2026-08-25
Omnicell, Inc. is rated a Hold; it faces near-term headwinds, with YoY revenue contraction, for the first time in seven quarters. Read more on OMCL stock here.

3 Small-Cap Stocks We Approach with Caution

2026-08-24
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Omnicell President Sells 6,753 Shares

2026-08-20
Nnamdi Njoku's disposal reduced his direct holdings by 4%, with over half tied to tax withholding from RSU vesting. He retains ~161,223 shares worth $5.81 million.

U.S. Physical Therapy Announces CFO

2026-08-14
HOUSTON, August 14, 2026--U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services ("IIP"), today announced that Nchacha Etta will serve as the Company’s Executive Vice President and Chief Financial Officer, effective as of September 1, 2026. Jason Curtis, the Company’s Senior Vice President, Finance and Accounting, served as Interim CFO since April 24, 2026.

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

2026-08-13
OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

OMCL Falls 20.1% in a Month as Booking and Margin Risks Build

2026-08-12
Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.

Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability

2026-08-04
In the past quarter, Omnicell, Inc. reported second-quarter 2026 revenue of US$312.21 million and net income of US$24.29 million, with both basic and diluted earnings per share from continuing operations rising compared with a year earlier, and also showed improved profitability for the first half of 2026. Omnicell also raised its full-year 2026 revenue guidance to a range of US$1.23 billion to US$1.25 billion and projected third-quarter 2026 revenue of US$301 million to US$307 million,...

Omnicell (OMCL) Stock May Be 42% Below Fair Value On Weak Guidance

2026-08-04
Omnicell stock is currently caught between two different valuation signals. The Discounted Cash Flow (DCF) estimate points to meaningful upside to intrinsic value, while market-based multiples suggest the shares already trade at a premium. Over the past 5 years Omnicell shareholders have seen the share price fall 77.6%, which sets a cautious backdrop for any claim that the stock now offers clear value. Recent product work at subsidiary EnlivenHealth, such as the VaxReach program to support...

Piper Sandler Reiterates Overweight on Omnicell, Lowers Price Target to $45

2026-08-03
Piper Sandler analyst Jessica Tassan reiterates Omnicell (NASDAQ:OMCL) with a Overweight and lowers the price target from $55 to $45.